City of Hope Reveals Vision for World-Class Cancer Care in Orange County

June 25, 2019 | City of Hope

City of Hope has accelerated its plans for a $1 billion comprehensive cancer campus in Orange County, bringing highly specialized cancer care, clinical trials, precision medicine and early detection to the nation’s sixth most populous county.

Continue Reading

City of Hope to participate in NCI-MATCH clinical trial

April 5, 2019 | City of Hope

City of Hope’s Clinical Molecular Diagnostic Laboratory (CMDL) is participating as a CLIA-Certified/Accredited laboratory in the NCI-Molecular Analysis for Therapy Choice (NCI-MATCH or EAY131) precision medicine trial.

Groundbreaking $2 million study will focus on family caregivers

October 15, 2018 | Maxine Nunes

City of Hope researchers have just received a $2 million grant from the National Cancer Institute to study a crucial but rarely examined aspect of patient care and quality of life — the family caregiver.

New Study: Deploying Genetic Screens Early May Offer Some Benefits

February 7, 2017 | Jyoti Madhusoodanan

Next-generation sequencing (NGS) tests can quickly pinpoint tumor mutations that can be targeted with specific drugs, offering a route to precision therapies for many cancer types. Coupled with new drugs that target tumor-specific genomic changes, NGS tests carry the potential to transform modern cancer care.

HPV vaccination: 4 facts you should know

January 27, 2016 | H. Chung So

Health experts agree that getting vaccinated against the human papillomavirus (HPV) is the easiest and most effective way to prevent cervical cancers. However, vaccination rates in the United States remain low, with only 40 percent of girls and 21 percent of boys having completed the three-dose cycle in 2015, according to the Centers for Disease Control and Prevention.

NCI-MATCH Trial focuses on mutations for rare cancers, not tumor site

April 15, 2015 | Nicole Levine

Precision medicine is becoming a reality for cancers with genetic mutations that are practically household names, such as those behind some breast cancers and lung cancers. A new multicenter trial focuses on providing precision treatments for rare cancers based on genetics, not tumor site.